Home > Journals > Giornale Italiano di Dermatologia e Venereologia > Past Issues > Giornale Italiano di Dermatologia e Venereologia 2012 December;147(6) > Giornale Italiano di Dermatologia e Venereologia 2012 December;147(6):563-71

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe PROMO
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Reprints

 

  CUTANEOUS LYMPHOMA: WHERE ARE WE MOVING? 

Giornale Italiano di Dermatologia e Venereologia 2012 December;147(6):563-71

Copyright © 2012 EDIZIONI MINERVA MEDICA

language: English

Advanced/aggressive CTCL: improving the efficacy of treatment

Zinzani P. L.

“L. e A. Seràgnoli” Institute of Hematology, University of Bologna, Bologna, Italy


PDF


Treatment regimens of patients with cutaneous T-cell lymphoma (CTCL) vary widely based on clinician preference and patient tolerance. Skin directed therapies are recommended for patients with early stage IA and IB MF, with combinations used in refractory cases. While no regimen has been proven to prolong survival in advanced stages, immunomodulatory regimens should be used initially to reduce the need for cytotoxic therapies. In more advanced stages of disease, treatment efforts should strive for palliation and improvement of quality of life. With many new therapies and strategies on the horizon, the future looks promising for CTCL patients.

top of page